Maxvax Biotechnology Limited Liability Company

This study tests a new shingles vaccine in 12,000 adults aged 40 and older to see how well it prevents shingles over 1 to 3 years after vaccination. Participants received two shots two months apart. The goal is to confirm the vaccine's long-term protection and safety.